Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Clear 100mg strength identification and batch code
The injection technique is standard subcutaneous
On June 10th, researchers from Eli Lilly published findings of a randomized phase 2a clinical trial in "Nature Medicine" titled Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. The study indicated that Retatrutide (LY3437943), a GLP-1R-related triple receptor agonist currently under clinical development, demonstrated significant efficacy and favorable safety in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD)
GLP-1 Supplement Dosage: How to Take
US$ 22.68
US$ 20.65
US$ 23.63
US$ 20.01
US$ 27.94
